Pediatric uveitis is an inflammatory disease involving iris, ciliary body and choroid. Compared with adult uveitis, pediatric uveitis has insidious onset and is easy to delay treatment. In recent years, biological agents have made remarkable progress in the treatment of non-infectious uveitis (NIU) in children. Anti-tumor necrosis factor-alpha drugs represented by Adalimumab have shown good effects in the control of inflammation, the saving of glucocorticoids, the frequency of uveitis attacks and the improvement of visual prognosis. At the same time, other biologics such as B cell antagonists, T cell antagonists, interleukin-6 antagonists and Janus kinase inhibitors were also gradually tested in children with NIU, bringing good news to children who failed to respond to anti-tumor necrosis factor-alpha drugs. With the in-depth understanding of the diagnosis and treatment of NIU children by clinicians, as well as the characteristics and therapeutic application of various biological agents, it is helpful to develop a more diversified and individualized treatment plan for children, so as to save the vision of children and children's families.
